Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01043250 |
Recruitment Status :
Completed
First Posted : January 6, 2010
Last Update Posted : July 25, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Schizophrenia Schizoaffective Disorder |
Study Type : | Observational |
Actual Enrollment : | 81 participants |
Observational Model: | Case-Only |
Time Perspective: | Retrospective |
Official Title: | Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain |
Study Start Date : | May 2009 |
Actual Primary Completion Date : | April 2010 |
Actual Study Completion Date : | December 2010 |

Group/Cohort |
---|
Risperidone
Receiving risperidone treatment
|
Olanzapine
Receiving olanzapine treatment
|
Aripiprazole
Receiving aripiprazole
|
- Changes in appetite and eating behavior Rating Scales: Drug-related eating behavior questionnaire & Korean version of General Food Craving Questionnaire [ Time Frame: between 2 and 24months after starting medication ]
- Body mass index (BMI) [ Time Frame: between 2 and 24 months after starting medication ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years to 59 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients meeting the DSM-IV criteria of schizophrenia, schizophreniform disorder, or schizoaffective disorder
- Male and female patients aged 19~59
- Patients receiving monotherapy with one of the three AAPs, i.e., olanzapine, risperidone, and aripiprazole for more than two and less than 24 months
- Patients who had at least one-week antipsychotics-free periods before starting the above antipsychotics
- Clinically stable and able to complete the questionnaires
- Patients who sufficiently understand the objective of the study and sign informed consent form
Exclusion Criteria:
- Patients having any medical illness or taking any medicine affecting appetite and body weight
- Patients with severe and unstable medical, neurological or systemic illnesses
- Patients having any comorbid psychiatric disorders including substance use disorders and eating disorders.
- Pregnant or breast-feeding women

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01043250
Korea, Republic of | |
Samsung Medical Center | |
Seoul, Korea, Republic of, 135-710 |
Principal Investigator: | Kyung Sue Hong, MD | Samsung Medical Center |
Responsible Party: | Kyung Sue Hong, M.D., Professor, Samsung Medical Center |
ClinicalTrials.gov Identifier: | NCT01043250 |
Other Study ID Numbers: |
2009-04-005 |
First Posted: | January 6, 2010 Key Record Dates |
Last Update Posted: | July 25, 2011 |
Last Verified: | July 2011 |
schizophrenia atypical antipsychotics appetite eating behavior |
Schizophrenia Psychotic Disorders Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders |